NDC 69097-361

grisofulvin

Grisofulvin

grisofulvin is a Oral Suspension in the Human Prescription Drug category. It is labeled and distributed by Cipla Usa Inc.. The primary component is Griseofulvin.

• Product ID: 69097-361_883762d6-5d17-4ccd-99e6-254a6ad208ef
• NDC: 69097-361
• Product Type: Human Prescription Drug
• Proprietary Name: grisofulvin
• Generic Name: Grisofulvin
• Dosage Form: Suspension
• Route of Administration: ORAL
• Marketing Start Date: 2017-03-06
• Marketing Category: ANDA / ANDA
• Application Number: ANDA065354
• Labeler Name: Cipla USA Inc.
• Substance Name: GRISEOFULVIN
• Active Ingredient Strength: 125 mg/5mL
• Pharm Classes: Decreased Mitosis [PE],Microtubule Inhibition [PE],Tubulin Inhibiting Agent [EPC]
• NDC Exclude Flag: N
• Listing Certified Through: 2020-12-31

Packaging

NDC 69097-361-08

120 mL in 1 BOTTLE (69097-361-08)

• Marketing Start Date: 2017-03-06
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 69097-361-08 [69097036108]

grisofulvin SUSPENSION

• Marketing Category: ANDA
• Application Number: ANDA065354
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2017-03-06

Drug Details

Active Ingredients

Ingredient	Strength
GRISEOFULVIN	125 mg/5mL

OpenFDA Data

• SPL SET ID: d5c737e5-51b8-4322-a2a5-4d4a392c1f56
• Manufacturer:
  • Cipla USA Inc.
• UNII:
  • 32HRV3E3D5
• RxNorm Concept Unique ID - RxCUI:
  • 239238
• UPC Code:
  • 0369097361082

Pharmacological Class

• Decreased Mitosis [PE]
• Microtubule Inhibition [PE]
• Tubulin Inhibiting Agent [EPC]
• Decreased Mitosis [PE]
• Microtubule Inhibition [PE]
• Tubulin Inhibiting Agent [EPC]

Medicade Reported Pricing

69097036108 GRISEOFULVIN 125 MG/5 ML SUSP

Pricing Unit: ML | Drug Type: